What have been the biggest headlines in industry this week? Take a look at our highlights including positive news about two monoclonal antibodies for relapsing multiple sclerosis and neuromyelitis optica spectrum disorder.
Browsing: monoclonal antibody
Positive results for Emgality® (galcanezumab) have been reported from the CONQUER study in patients who failed previous migraine preventive treatments.
In this interview, Jeffrey Cummings speaks to us about the current landscape around antibody therapeutics for Alzheimer’s disease.
In this review article, published in the journal Immunotherapy, the authors explore immunotherapy for neuroblastoma from therapeutic backbone to the latest discoveries.
Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer’s disease?
In this Editorial published in Immunotherapy, researchers explore the use of antibodies directed against amyloid-β oligomers for Alzheimer’s disease.
Novartis has announced that the EMA has granted license for the use of Aimovig® (erenumab) for the prevention of migraine in adults.
Aimovig® (erenumab) has received a positive opinion from the CHMP for migraine, steering the way towards a marketing authorization from the EMA.